974 related articles for article (PubMed ID: 21712506)
21. Clinical use of unfractionated heparin therapy in children: time for change?
Newall F; Ignjatovic V; Johnston L; Summerhayes R; Lane G; Cranswick N; Monagle P
Br J Haematol; 2010 Sep; 150(6):674-8. PubMed ID: 20629660
[TBL] [Abstract][Full Text] [Related]
22. Monitoring unfractionated heparin therapy with antifactor Xa activity results in fewer monitoring tests and dosage changes than monitoring with the activated partial thromboplastin time.
Rosborough TK
Pharmacotherapy; 1999 Jun; 19(6):760-6. PubMed ID: 10391423
[TBL] [Abstract][Full Text] [Related]
23. Thrombin formation and effect of unfractionated heparin during pediatric cardiac catheterization.
Chen D; Långström S; Petäjä J; Heikinheimo M; Pihkala J
Catheter Cardiovasc Interv; 2013 Jun; 81(7):1174-9. PubMed ID: 22915548
[TBL] [Abstract][Full Text] [Related]
24. Anticoagulation monitoring part 2: Unfractionated heparin and low-molecular-weight heparin.
Spinler SA; Wittkowsky AK; Nutescu EA; Smythe MA
Ann Pharmacother; 2005; 39(7-8):1275-85. PubMed ID: 15956240
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of weight-based dosing of unfractionated heparin in obese children.
Taylor BN; Bork SJ; Kim S; Moffett BS; Yee DL
J Pediatr; 2013 Jul; 163(1):150-3. PubMed ID: 23414664
[TBL] [Abstract][Full Text] [Related]
26. Unfractionated heparin dose requirements targeting intermediate intensity antifactor Xa concentration during pregnancy.
Clark NP; Delate T; Cleary SJ; Witt DM
Pharmacotherapy; 2010 Apr; 30(4):369-74. PubMed ID: 20334457
[TBL] [Abstract][Full Text] [Related]
27. Comparison of anti-Xa and activated partial thromboplastin time monitoring for heparin dosing in patients with cirrhosis.
Fuentes A; Gordon-Burroughs S; Hall JB; Putney DR; Monsour HP
Ther Drug Monit; 2015 Feb; 37(1):40-4. PubMed ID: 24901494
[TBL] [Abstract][Full Text] [Related]
28. Monitoring of unfractionated heparin using activated partial thromboplastin time: an assessment of the current nomogram and analysis according to age.
Kim JS; Lee HJ; Sung JD; Kim HJ; Lee SY; Kim JS
Clin Appl Thromb Hemost; 2014 Oct; 20(7):723-8. PubMed ID: 23615295
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Managing Factor Xa Inhibitor to Unfractionated Heparin Transitions by aPTT Versus a Treatment Guideline Utilizing Heparin Anti-Xa Levels.
Dingus SJ; Smith AR; Dager WE; Zochert S; Nothdurft SA; Gulseth MP
Ann Pharmacother; 2022 Dec; 56(12):1289-1298. PubMed ID: 35499336
[TBL] [Abstract][Full Text] [Related]
30. Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support.
Adatya S; Uriel N; Yarmohammadi H; Holley CT; Feng A; Roy SS; Reding MT; John R; Eckman P; Zantek ND
JACC Heart Fail; 2015 Apr; 3(4):314-22. PubMed ID: 25770404
[TBL] [Abstract][Full Text] [Related]
31. Performance Assessment of a Multifaceted Unfractionated Heparin Dosing Protocol in Adult Patients on Extracorporeal Membrane Oxygenator.
Al-Jazairi A; Raslan S; Al-Mehizia R; Dalaty HA; De Vol EB; Saad E; Alanazi M; Owaidah T
Ann Pharmacother; 2021 May; 55(5):592-604. PubMed ID: 32959678
[TBL] [Abstract][Full Text] [Related]
32. Partial thromboplastin time is more predictive of bleeding than anti-Xa levels in heparinized pediatric patients after cardiac surgery.
Oladunjoye OO; Sleeper LA; Nair AG; Trenor CC; VanderPluym C; Kheir JN; Emani SM
J Thorac Cardiovasc Surg; 2018 Jul; 156(1):332-340.e1. PubMed ID: 29709361
[TBL] [Abstract][Full Text] [Related]
33. Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children.
Kuhle S; Eulmesekian P; Kavanagh B; Massicotte P; Vegh P; Lau A; Mitchell LG
Haematologica; 2007 Apr; 92(4):554-7. PubMed ID: 17488668
[TBL] [Abstract][Full Text] [Related]
34. In vivo age dependency of unfractionated heparin in infants and children.
Newall F; Ignjatovic V; Summerhayes R; Gan A; Butt W; Johnston L; Monagle P
Thromb Res; 2009 Mar; 123(5):710-4. PubMed ID: 18829072
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy.
McLaughlin K; Rimsans J; Sylvester KW; Fanikos J; Dorfman DM; Senna P; Connors JM; Goldhaber SZ
Clin Appl Thromb Hemost; 2019; 25():1076029619876030. PubMed ID: 31530176
[TBL] [Abstract][Full Text] [Related]
36. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Antifactor Xa and Activated Partial Thromboplastin Time Monitoring for Heparin Dosing in Vascular Surgery Patients: A Single-Center Retrospective Study.
Rizk E; Wilson AD; Murillo MU; Putney DR
Ther Drug Monit; 2018 Feb; 40(1):151-155. PubMed ID: 29120972
[TBL] [Abstract][Full Text] [Related]
38. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
[TBL] [Abstract][Full Text] [Related]
39. Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit.
Novelli C; Borotto E; Beverina I; Punzi V; Radrizzani D; Brando B
Int J Lab Hematol; 2021 Dec; 43(6):1284-1290. PubMed ID: 33855802
[TBL] [Abstract][Full Text] [Related]
40. Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations.
Marlar RA; Clement B; Gausman J
Semin Thromb Hemost; 2017 Apr; 43(3):253-260. PubMed ID: 27272964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
